Clinical trial
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
NCT02849132 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
- Lead sponsor
- Beijing Friendship Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 31, 2016
- Completion date
- December 31, 2025
- Enrollment
- 800 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.